United States Biotechnology & Medical Research

Acrivon Therapeutics Inc (ACRV)

Track

Track

Acrivon Therapeutics experienced ten insider trading transactions over the past ninety days, resulting in a net negative value of approximately $39,806. Executives, including the CEO, offloaded shares following the August earnings report. These divestments occurred while the stock price showed an 11.8% increase during this period, reflecting recent market performance trends.
Ticker: ACRV Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Acrivon Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.7
Blume-Jensen Peter President and CEO Executive Director
Transaction date
Sale
Price
240.04
Quantity 87,833 +25.0%
Value US$4,648,169
2.7
Peter Blume-Jensen Officer; Director Executive Director
Transaction date
Proposed sale
Price
370.63
Quantity 68,688
Value US$466,436
Peterson Katharine Chief Accounting Officer Officer
Transaction date
Sale
Price
120.88
Quantity 43,180 +2.3%
Value US$3,707,938
3.4
Miller Mary Chief Legal Officer Officer
Transaction date
Sale
Price
2.01
Quantity 185 -0.2%
Value US$372
Gamelin Erick Chief Development Officer Officer
Transaction date
Sale
Price
2.01
Quantity 400 -0.8%
Value US$804
2.0
Devroe Eric Chief Operating Officer Officer
Transaction date
Sale
Price
2.01
Quantity 604 -0.4%
Value US$1,214
2.7
Blume-Jensen Peter President and CEO Executive Director
Transaction date
Sale
Price
2.01
Quantity 484 -0.1%
Value US$973
2.7
Blume-Jensen Peter President and CEO Executive Director
Transaction date
Sale
Price
2.01
Quantity 1,229 -0.1%
Value US$2,470
1.4
Levy Adam D. Chief Financial Officer Officer
Transaction date
Sale
Price
1.57
Quantity 1,142 -1.7%
Value US$1,793
3.4
Miller Mary Chief Legal Officer Officer
Transaction date
Sale
Price
1.76
Quantity 573 -0.7%
Value US$1,008
1.4
Levy Adam D. Chief Financial Officer Officer
Transaction date
Purchase
Price
1.70
Quantity 8,832 +72.7%
Value US$14,999
2.7
Blume-Jensen Peter President and CEO Executive Director
Transaction date
Purchase
Price
1.68
Quantity 49,000 +2.4%
Value US$82,124
2.0
Devroe Eric Chief Operating Officer Officer
Transaction date
Purchase
Price
1.72
Quantity 10,000 +15.3%
Value US$17,218
2.7
PERCEPTIVE ADVISORS LLC Large shareholder
Transaction date
Sale
Price
1.41
Quantity 437,881 -11.4%
Value US$617,412
2.7
PERCEPTIVE ADVISORS LLC Large shareholder
Transaction date
Sale
Price
1.41
Quantity 250,000 -6.1%
Value US$352,500
2.7
PERCEPTIVE ADVISORS LLC Large shareholder
Transaction date
Sale
Price
1.56
Quantity 215,283 -5.0%
Value US$335,841
2.7
PERCEPTIVE ADVISORS LLC Large shareholder
Transaction date
Sale
Price
1.95
Quantity 1,054,669 -19.7%
Value US$2,056,605
2.7
PERCEPTIVE ADVISORS LLC Large shareholder
Transaction date
Purchase
Price
8.50
Quantity 2,353,000 +78.2%
Value US$20,000,500
1.5
Chione Ltd Large shareholder
Transaction date
Sale
Price
12.93
Quantity 16 -0.0%
Value US$207
1.5
Chione Ltd Large shareholder
Transaction date
Sale
Price
12.14
Quantity 2,056 -0.1%
Value US$24,960
1.5
Chione Ltd Large shareholder
Transaction date
Sale
Price
12.13
Quantity 893 -0.0%
Value US$10,832
1.5
Chione Ltd Large shareholder
Transaction date
Sale
Price
12.30
Quantity 3,000 -0.1%
Value US$36,900
1.5
Chione Ltd Large shareholder
Transaction date
Sale
Price
12.34
Quantity 2,000 -0.1%
Value US$24,680
1.5
Chione Ltd 10% Stockholder Large shareholder
Transaction date
Proposed sale
Price
12.44
Quantity 219,259
Value US$2,727,594
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
12.50
Quantity 3,389,500 +340.8%
Value US$42,368,750
1.5
Chione Ltd Large shareholder
Transaction date
Purchase
Price
12.50
Quantity 400,000 +11.6%
Value US$5,000,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-27 2026-08-25 S Sale
2.7
Blume-Jensen Peter

President and CEO

Executive Director
87,833 +25.0%
240.04
US$4,648,169 		87,833 +25.0% 240.04 US$4,648,169
2026-08-25 2026-08-25 PrS Proposed sale
2.7
Peter Blume-Jensen

Officer; Director

Executive Director
68,688
370.63
US$466,436 		68,688 370.63 US$466,436
2026-08-20 2026-08-18 S Sale
Peterson Katharine

Chief Accounting Officer

Officer
43,180 +2.3%
120.88
US$3,707,938 		43,180 +2.3% 120.88 US$3,707,938
2026-08-20 2026-08-18 S Sale
3.4
Miller Mary

Chief Legal Officer

Officer
185 -0.2%
2.01
US$372 		185 -0.2% 2.01 US$372
2026-08-20 2026-08-18 S Sale
Gamelin Erick

Chief Development Officer

Officer
400 -0.8%
2.01
US$804 		400 -0.8% 2.01 US$804
2026-08-20 2026-08-18 S Sale
2.0
Devroe Eric

Chief Operating Officer

Officer
604 -0.4%
2.01
US$1,214 		604 -0.4% 2.01 US$1,214
2026-08-20 2026-08-18 S Sale
2.7
Blume-Jensen Peter

President and CEO

Executive Director
484 -0.1%
2.01
US$973 		484 -0.1% 2.01 US$973
2026-08-20 2026-08-18 S Sale
2.7
Blume-Jensen Peter

President and CEO

Executive Director
1,229 -0.1%
2.01
US$2,470 		1,229 -0.1% 2.01 US$2,470
2026-08-06 2026-08-04 S Sale
1.4
Levy Adam D.

Chief Financial Officer

Officer
1,142 -1.7%
1.57
US$1,793 		1,142 -1.7% 1.57 US$1,793
2026-07-23 2026-07-21 S Sale
3.4
Miller Mary

Chief Legal Officer

Officer
573 -0.7%
1.76
US$1,008 		573 -0.7% 1.76 US$1,008
2026-01-16 2026-01-14 B Purchase
1.4
Levy Adam D.

Chief Financial Officer

Officer
8,832 +72.7%
1.70
US$14,999 		8,832 +72.7% 1.70 US$14,999
2026-01-16 2026-01-14 B Purchase
2.7
Blume-Jensen Peter

President and CEO

Executive Director
49,000 +2.4%
1.68
US$82,124 		49,000 +2.4% 1.68 US$82,124
2026-01-15 2026-01-13 B Purchase
2.0
Devroe Eric

Chief Operating Officer

Officer
10,000 +15.3%
1.72
US$17,218 		10,000 +15.3% 1.72 US$17,218
2025-05-01 2025-05-01 S Sale
2.7
PERCEPTIVE ADVISORS LLC
Large shareholder
298,886 -8.8%
1.34
US$400,507 		298,886 -8.8% 1.34 US$400,507
2025-05-01 2025-04-30 S Sale
2.7
PERCEPTIVE ADVISORS LLC
Large shareholder
437,881 -11.4%
1.41
US$617,412 		437,881 -11.4% 1.41 US$617,412
2025-04-29 2025-04-29 S Sale
2.7
PERCEPTIVE ADVISORS LLC
Large shareholder
250,000 -6.1%
1.41
US$352,500 		250,000 -6.1% 1.41 US$352,500
2025-04-29 2025-04-28 S Sale
2.7
PERCEPTIVE ADVISORS LLC
Large shareholder
215,283 -5.0%
1.56
US$335,841 		215,283 -5.0% 1.56 US$335,841
2025-04-29 2025-04-25 S Sale
2.7
PERCEPTIVE ADVISORS LLC
Large shareholder
1,054,669 -19.7%
1.95
US$2,056,605 		1,054,669 -19.7% 1.95 US$2,056,605
2024-04-15 2024-04-11 B Purchase
2.7
PERCEPTIVE ADVISORS LLC
Large shareholder
2,353,000 +78.2%
8.50
US$20,000,500 		2,353,000 +78.2% 8.50 US$20,000,500
2023-06-28 2023-06-26 S Sale
1.5
Chione Ltd
Large shareholder
16 -0.0%
12.93
US$207 		16 -0.0% 12.93 US$207
2023-06-20 2023-06-15 S Sale
1.5
Chione Ltd
Large shareholder
2,056 -0.1%
12.14
US$24,960 		2,056 -0.1% 12.14 US$24,960
2023-06-14 2023-06-14 S Sale
1.5
Chione Ltd
Large shareholder
893 -0.0%
12.13
US$10,832 		893 -0.0% 12.13 US$10,832
2023-06-14 2023-06-13 S Sale
1.5
Chione Ltd
Large shareholder
3,000 -0.1%
12.30
US$36,900 		3,000 -0.1% 12.30 US$36,900
2023-06-14 2023-06-12 S Sale
1.5
Chione Ltd
Large shareholder
2,000 -0.1%
12.34
US$24,680 		2,000 -0.1% 12.34 US$24,680
2023-06-12 2023-06-12 PrS Proposed sale
1.5
Chione Ltd

10% Stockholder

Large shareholder
219,259
12.44
US$2,727,594 		219,259 12.44 US$2,727,594
2022-11-21 2022-11-17 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
3,389,500 +340.8%
12.50
US$42,368,750 		3,389,500 +340.8% 12.50 US$42,368,750
2022-11-21 2022-11-17 B Purchase
1.5
Chione Ltd
Large shareholder
400,000 +11.6%
12.50
US$5,000,000 		400,000 +11.6% 12.50 US$5,000,000
Explore more

More insider trading research around Acrivon Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America